RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3K, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer modelsErmira Pazolli,Randy Kipp,Alessandro Boezio,Hakan Gunaydin,Amanda Iskandar,Matthew Zubrowski,Bret Williams,Kelley Shortsleeves,Alexandre Larivee,Tom McLean,Klaus Michelsen,Hongtao Zeng,Jonathan LaRochelle,Joe Manna,Lucian DiPietro,Andre Lescarbeau,Mary Mader,Bindu Bennet,Jeremy Wilbur,Qi Wang,Levi Pierce,Iain Martin,James Watters,Pascal Fortin,Donald BergstromCANCER RESEARCH（2022）引用 0|浏览24暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
